

TAKING THE NEXT STEP IN
**Parkinson's
Disease**
RESEARCH




**A Clinical Research Study for
Newly or Recently Diagnosed Patients**

The **SPARK** study is evaluating an investigational drug that targets alpha-synuclein (α -syn), a molecule associated with Parkinson's disease, to see if it may potentially help to slow or reduce progression in the earliest stages of the disease. If you have been diagnosed within the past three years, are between 40 and 80 years of age (inclusive), and have not received levodopa to manage symptoms, you may be eligible to participate.

To see if you qualify,
contact our study center:

Ray James, BS, RN
617-638-7745
rcjames@bu.edu

**All eligible study participants will
receive at no cost:**

-  Investigational drug (at some point during study participation)
-  Study-related care, consultation, and visits
-  Reimbursement for study-related expenses and travel assistance (if necessary)

theSPARKstudy.com

spark 